31 results
P
adults with ureteral stones
I/C
mirabegron (50 mg daily), control group
O
stone expulsion rate, stone expulsion interval, pain episodes
P
patients with >1cm kidney stones
I/C
miniaturized percutaneous nephrolithotomy (mPCNL), retrograde intrarenal surgery (RIRS)
O
stone-free rate, hemoglobin drop, transfusion rate, length of hospital stay, complications
P
I/C
l, o, w, -, l, e, v, e, l, , a, r, s, e, n, i, c, , (, A, s, ), , c, o, n, c, e, n, t, r, a, t, i, o, n, , i, n, , d, r, i, n, k, i, n, g, , w, a, t, e, r, d, r, i, n, k, i, n, g, , w, a, t, e, r, , A, s, , c, o, n, c, e, n, t, r, a, t, i, o, n, s, , l, o, w, e, r, , t, h, a, n, , t, h, e, , W, H, O, , p, r, o, v, i, s, i, o, n, a, l, , g, u, i, d, e, l, i, n, e, , v, a, l, u, e, , (, 1, 0, , µ, g, /, L, )
O
p, o, o, l, e, d, , a, s, s, o, c, i, a, t, i, o, n, , b, e, t, w, e, e, n, , t, h, e, , r, e, l, a, t, i, v, e, , r, i, s, k, , o, f, , e, a, c, h, , c, a, r, d, i, o, v, a, s, c, u, l, a, r, , d, i, s, e, a, s, e, , (, C, V, D, ), , e, n, d, p, o, i, n, t, , a, n, d, , l, o, w, -, l, e, v, e, l, , A, s, , c, o, n, c, e, n, t, r, a, t, i, o, n, , i, n, , d, r, i, n, k, i, n, g, , w, a, t, e, r
P
tea intake
I/C
tea intake, kidney stones
O
decreased risk
P
children
I/C
adult-sized instruments, pediatric-sized instruments
O
stone-free rate, initial stone-free rate, final stone-free rate, residual stones, overall complication rates, hemoglobin/hematocrit decrease
P
DM, MetS, IGT
I/C
chronic hyperglycaemia, No chronic hyperglycaemia
O
developing kidney stone disease
P
patients with ureteral calculi
I/C
alpha-adrenergic blockers (tamsulosin, alfuzosin, doxazosin, terazosin, naftopidil, or silodosin), placebo
O
clearance of stones in the urinary tract, treating distal urinary tract stones, adverse events (dizziness, retrograde ejaculation)
P
patients with urolithiasis
I/C
dual-energy CT (DECT), stone analysis
O
accuracy of DECT for diagnosis of uric acid calculi in vivo
P
patients with localized infections
I/C
antibiotics formulated at concentrations between 0 and 6% w/w into bone cements, gentamycin-infused bone cement mixtures
O
eradication or delay of infection onset
P
kidney stone formers (KSF)
I/C
data synthesis, coronary artery disease (CAD), stroke/transient ischemic attacks (TIA), arterial disease (AD)
O
25% higher risk, 17% higher risk, 39% higher risk